Abstract
Patients with hematological malignancies are at increased risk of severe COVID-19 outcomes due to compromised immune responses, but the insights of these studies have been compromised due to intrinsic limitations in study design. Here we present the PROSECO prospective observational study ( NCT04858568 ) on 457 patients with lymphoma that received two or three COVID-19 vaccine doses. We show undetectable humoral responses following two vaccine doses in 52% of patients undergoing active anticancer treatment. Moreover, 60% of patients on anti-CD20 therapy had undetectable antibodies following full vaccination within 12 months of receiving their anticancer therapy. However, 70% of individuals with indolent B-cell lymphoma displayed improved antibody responses following booster vaccination. Notably, 63% of all patients displayed antigen-specific T-cell responses, which increased after a third dose irrespective of their cancer treatment status. Our results emphasize the urgency of careful monitoring of COVID-19-specific immune responses to guide vaccination schemes in these vulnerable populations.
【초록키워드】 Treatment, COVID-19 vaccine, immune response, vaccination, therapy, severe COVID-19, antibody, Hematological malignancy, Hematological malignancies, prospective observational study, Antibody Response, outcome, observational study, anti-CD20 therapy, Antigen, vaccine dose, Humoral response, B-cell lymphoma, lymphoma, immune responses, Patient, Study design, cancer treatment, T-cell responses, anti-CD20, booster vaccination, dose, increased risk, individual, urgency, doses, anticancer, populations, indolent, intrinsic limitations, receiving, intrinsic limitation, undetectable, 【제목키워드】 Vaccine, SARS-CoV-2 variant, B-cell, dose, responses against,